Alphamab Oncology has announced research updates regarding its investigational drug JSKN003 at the ESMO Congress 2025, held from October 17 to October 21, 2025. The updates include data from a phase I/II clinical study evaluating the efficacy and safety of JSKN003 in Chinese patients with advanced solid tumors, specifically those with primary platinum-refractory ovarian cancer $(OC)$. As of June 13, 2025, a total of 26 patients received JSKN003 at a dose of 6.3mg/kg every three weeks. The company also outlined the ongoing phase III clinical trial, which aims to enroll 556 patients across 80 sites in China. Patient recruitment began in February 2025 and is ongoing. JSKN003 is described as a biparatopic HER2-targeting antibody-drug conjugate linked to a topoisomerase I inhibitor. The company cautioned that there is no guarantee of successful development or commercialization of JSKN003.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.